MX391400B - Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato. - Google Patents

Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.

Info

Publication number
MX391400B
MX391400B MX2017006561A MX2017006561A MX391400B MX 391400 B MX391400 B MX 391400B MX 2017006561 A MX2017006561 A MX 2017006561A MX 2017006561 A MX2017006561 A MX 2017006561A MX 391400 B MX391400 B MX 391400B
Authority
MX
Mexico
Prior art keywords
dimethyl fumarate
formulations including
matrix formulations
pharmaceutical compositions
present
Prior art date
Application number
MX2017006561A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006561A (es
Inventor
Cheuk- Yui LEUNG
Peter Zawaneh
Shyam B Karki
Yiqing Lin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2017006561A publication Critical patent/MX2017006561A/es
Publication of MX391400B publication Critical patent/MX391400B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017006561A 2014-11-19 2015-11-19 Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato. MX391400B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081907P 2014-11-19 2014-11-19
PCT/US2015/061448 WO2016081671A1 (en) 2014-11-19 2015-11-19 Pharmaceutical matrix formulations comprising dimethyl fumarate

Publications (2)

Publication Number Publication Date
MX2017006561A MX2017006561A (es) 2018-02-21
MX391400B true MX391400B (es) 2025-03-21

Family

ID=54838418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006561A MX391400B (es) 2014-11-19 2015-11-19 Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.

Country Status (13)

Country Link
US (2) US20190083404A1 (enExample)
EP (1) EP3220897A1 (enExample)
JP (2) JP6901393B2 (enExample)
KR (1) KR20170086053A (enExample)
CN (2) CN113262205A (enExample)
AU (2) AU2015349891B2 (enExample)
CA (1) CA2967645A1 (enExample)
EA (1) EA201791089A1 (enExample)
HK (1) HK1244215A1 (enExample)
IL (1) IL252105A0 (enExample)
MA (1) MA40990A (enExample)
MX (1) MX391400B (enExample)
WO (1) WO2016081671A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987895A1 (en) 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
KR102714380B1 (ko) 2021-06-09 2024-10-11 강원대학교산학협력단 경구 투여용 나노입자 및 이의 제조방법
WO2023036702A1 (en) 2021-09-09 2023-03-16 It Pharmagus Limited Method for the manufacturing of a solid body as an oral dosage form of a pharmaceutical or a food supplement

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1207866E (pt) * 1999-08-31 2005-02-28 Gruenenthal Gmbh Forma de administracao retardada contendo sacarinato de tramadol
EP1886665A1 (en) * 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CN109044985A (zh) * 2009-01-09 2018-12-21 前进制药知识产权有限公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
NZ617130A (en) * 2009-04-29 2015-06-26 Biogen Ma Inc Treatment of neurodegeneration and neuroinflammation
CA2827990A1 (en) * 2011-02-25 2012-08-30 The Johns Hopkins University Chalcone derivatives as nrf2 activators
US20130158077A1 (en) * 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
AU2013203445C1 (en) * 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
AU2013305684B2 (en) * 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP3566701A1 (en) * 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
CN105369562B (zh) * 2014-08-28 2019-12-20 青岛海尔洗衣机有限公司 一种带有防衣物褪色提醒功能的洗衣机

Also Published As

Publication number Publication date
AU2021204247A1 (en) 2021-07-22
CA2967645A1 (en) 2016-05-26
EA201791089A1 (ru) 2017-11-30
MA40990A (fr) 2017-09-26
JP2017534667A (ja) 2017-11-24
MX2017006561A (es) 2018-02-21
KR20170086053A (ko) 2017-07-25
IL252105A0 (en) 2017-07-31
CN107205942A (zh) 2017-09-26
HK1244215A1 (zh) 2018-08-03
US20190175510A1 (en) 2019-06-13
JP2021152046A (ja) 2021-09-30
CN113262205A (zh) 2021-08-17
US20190083404A1 (en) 2019-03-21
AU2015349891B2 (en) 2021-04-01
JP6901393B2 (ja) 2021-07-14
EP3220897A1 (en) 2017-09-27
AU2015349891A1 (en) 2017-05-25
WO2016081671A1 (en) 2016-05-26
WO2016081671A8 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2020005446A (es) Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
PL3316867T3 (pl) Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
CA3027725C (en) SYNTHESIS OF GSK23390672 BY EPOXY HYDROLASE RESOLUTION
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX391400B (es) Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.
DK3129057T3 (da) Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2017002229A1 (es) Inhibidores de bace1.
HUE066387T2 (hu) Polimerizált gyógyszert tartalmazó gyógyszerészeti készítmény